4:16 PM ET
8-K
Business Update
Immix Biopharma Business Update
Immix Biopharma reported its Q3 2026 operational progress, highlighting an 89% complete response rate in its NEXICART-2 clinical trial for NXC-201. The company strengthened its leadership team with new SVPs of Technical Operations and Regulatory Affairs as it prepares for a planned BLA submission in mid-2027.